Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer treatment, with its lead asset MARGENZA (margetuximab) approved for HER2+ metastatic breast cancer in combination with chemotherapy. The company operates a proprietary DART platform for bispecific antibodies and maintains a pipeline of early-to-mid stage oncology candidates including vobramitamab duocarmazine and lorigerlimab. With a $100M market cap, negative operating cash flow of $100M annually, and 5.22x current ratio, MGNX represents a high-risk, pre-profitability biotech dependent on clinical trial outcomes and partnership economics.
MacroGenics generates revenue through two channels: (1) direct commercial sales of MARGENZA in the US for HER2+ breast cancer, competing against Herceptin biosimilars and Enhertu, with limited pricing power due to competitive intensity; (2) upfront payments, development milestones, and royalties from licensing its proprietary antibody platforms (DART, Fc optimization) to larger pharma partners. The 91.7% gross margin reflects low cost of goods for biologics but is offset by massive R&D burn ($70-80M annually estimated) across multiple Phase 1/2 programs. The company lacks sustainable profitability without either blockbuster clinical data or transformative partnerships, making it a binary bet on pipeline execution.
Phase 2/3 clinical trial data readouts for vobramitamab duocarmazine (antibody-drug conjugate) and lorigerlimab (PD-1 x CTLA-4 bispecific)
FDA regulatory decisions on Biologics License Applications or breakthrough therapy designations for pipeline assets
Partnership announcements with big pharma for platform licensing deals (upfront payments $50-200M typical range)
MARGENZA quarterly sales performance versus Street estimates and competitive positioning against Enhertu
Cash runway updates and equity financing announcements given negative $100M annual cash burn
Antibody-drug conjugate (ADC) market saturation with Enhertu, Trodelvy, and 15+ competing programs creating high bar for differentiation and pricing power erosion
FDA regulatory pathway uncertainty for bispecific antibodies with evolving safety monitoring requirements post-approval
Reimbursement pressure from PBMs and payers demanding real-world evidence for incremental survival benefits versus standard-of-care, particularly in crowded HER2+ breast cancer indication
MARGENZA faces direct competition from Daiichi Sankyo's Enhertu (superior efficacy data) and Roche Herceptin biosimilars (lower cost), limiting market share to third-line settings
Pipeline programs compete against better-capitalized big pharma with faster enrollment and broader trial networks (e.g., Merck, BMS in immuno-oncology)
Platform technology risk as DART bispecifics face competition from Amgen's BiTE, Regeneron's bispecifics, and emerging trispecific formats
Cash burn of $100M annually against $100M market cap creates imminent dilution risk, with potential 50-100% share count increase needed for 18-month runway extension
Debt/equity of 0.55x manageable currently but limits flexibility for additional borrowing if equity markets close
Partnership dependency risk as 50-60% of revenue relies on milestone payments that are binary and unpredictable, creating lumpy cash flow profile
low - Oncology drug demand is non-discretionary and insulated from GDP fluctuations. Cancer patients require treatment regardless of economic conditions. However, hospital budget constraints during recessions can delay formulary adoption of premium-priced biologics. Clinical trial enrollment may slow modestly if patients defer elective procedures, but Phase 2/3 oncology trials typically maintain momentum.
Rising interest rates negatively impact MGNX through two channels: (1) Higher discount rates compress NPV of future pipeline assets, particularly punishing pre-revenue biotechs with cash flows 5-10 years out; (2) Increased cost of capital makes equity financing more dilutive, forcing worse terms on secondary offerings needed to fund $100M annual burn. The 10-year Treasury yield directly affects biotech sector valuation multiples, with 100bps rate increases historically compressing EV/Sales multiples by 15-20% for clinical-stage names.
Minimal direct credit exposure. With 0.55x debt/equity and strong 5.22x current ratio, MGNX maintains adequate liquidity. However, tightening credit conditions reduce availability of venture debt or convertible financing, forcing reliance on dilutive equity raises. High-yield credit spreads widening above 500bps historically correlates with biotech financing windows closing, creating existential risk for cash-burning clinical-stage companies.
growth - Attracts speculative biotech investors and hedge funds making binary bets on clinical catalysts. With -98.3% ROE and negative cash flow, this is purely a growth/momentum story dependent on pipeline optionality. Not suitable for value or income investors. Typical holders include biotech-focused funds willing to underwrite 70-80% downside risk for 300-500% upside on positive Phase 3 data. The 159.4% revenue growth attracts momentum traders despite underlying partnership lumpiness.
high - Clinical-stage biotechs with <$200M market caps routinely experience 30-50% single-day moves on trial data. Beta likely 1.8-2.2x versus broader market. The -39.7% one-year return with recent 12-13% quarterly bounces demonstrates extreme volatility. Options market typically prices 80-100% implied volatility around data catalyst events. Illiquidity with small float amplifies price swings on modest volume.